# Hidradenitis Suppurativa (HS) FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/hidradenitis-suppurativa-hs

> 12 upcoming FDA catalysts in hidradenitis Suppurativa (HS): Povofortay (povorcitinib, INCY) on Dec 2026 to Mar 2027 (topline data readout); Povofortay (povorcitinib, INCY) on December 2026 (primary completion); SPY072 (SYRE) on October 2027 (primary completion); SPY072 (SYRE) on Oct 2027 to Jan 2028 (topline data readout); and 8 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| September 18, 2026 | [APPROACH (tibulizumab) primary completion](https://sec-api.dev/pdufa/tibulizumab) | ZURA | Hidradenitis Suppurativa (HS) | completed | "NCT06993610 (Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-09-18 (ACTUAL); Lead Sponsor Zura Bio Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06993610)) |
| Q4 2026 | [APPROACH (tibulizumab) topline data readout](https://sec-api.dev/pdufa/tibulizumab) | ZURA | Hidradenitis Suppurativa (HS) | scheduled | "Phase 2 clinical trial (TibuSURE) ongoing; topline data anticipated in Q4 2026 Tibulizumab, is an investigational agent." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1855644/000110465925087286/tm2525151d1_ex99-1.htm)) |
| Dec 2026 to Mar 2027 | [Povofortay (povorcitinib) topline data readout](https://sec-api.dev/pdufa/povorcitinib) | INCY | Hidradenitis Suppurativa (HS) | scheduled | "NCT06212999 (A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-26 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06212999)) |
| December 2026 | [Povofortay (povorcitinib) primary completion](https://sec-api.dev/pdufa/povorcitinib) | INCY | Hidradenitis Suppurativa (HS) | scheduled | "NCT06212999 (A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-26 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06212999)) |
| October 2027 | [SPY072 primary completion](https://sec-api.dev/pdufa/spy072) | SYRE | Hidradenitis Suppurativa (HS) | scheduled | "NCT07766005 (A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-10 (ESTIMATED); Lead Sponsor Spyre Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07766005)) |
| Oct 2027 to Jan 2028 | [SPY072 topline data readout](https://sec-api.dev/pdufa/spy072) | SYRE | Hidradenitis Suppurativa (HS) | scheduled | "NCT07766005 (A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-10 (ESTIMATED); Lead Sponsor Spyre Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07766005)) |
| Feb to May 2028 | [Povofortay (povorcitinib) topline data readout](https://sec-api.dev/pdufa/povorcitinib) | INCY | Hidradenitis Suppurativa (HS) | scheduled | "NCT06855498 (Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-28 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06855498)) |
| February 2028 | [SL-325 primary completion](https://sec-api.dev/pdufa/sl-325) | STTK | Hidradenitis Suppurativa (HS) | scheduled | "NCT07934017 (A Study of SL-325 in Participants With Hidradenitis Suppurativa): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-02 (ESTIMATED); Lead Sponsor Shattuck Labs, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07934017)) |
| Feb to May 2028 | [SL-325 topline data readout](https://sec-api.dev/pdufa/sl-325) | STTK | Hidradenitis Suppurativa (HS) | scheduled | "NCT07934017 (A Study of SL-325 in Participants With Hidradenitis Suppurativa): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-02 (ESTIMATED); Lead Sponsor Shattuck Labs, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07934017)) |
| February 2028 | [Povofortay (povorcitinib) primary completion](https://sec-api.dev/pdufa/povorcitinib) | INCY | Hidradenitis Suppurativa (HS) | scheduled | "NCT06855498 (Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-28 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06855498)) |
| Mar to Jun 2028 | [Povofortay (povorcitinib) topline data readout](https://sec-api.dev/pdufa/povorcitinib) | INCY | Hidradenitis Suppurativa (HS) | scheduled | "NCT07213973 (Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-03-25 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07213973)) |
| March 2028 | [Povofortay (povorcitinib) primary completion](https://sec-api.dev/pdufa/povorcitinib) | INCY | Hidradenitis Suppurativa (HS) | scheduled | "NCT07213973 (Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-03-25 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07213973)) |
| October 2028 | [ORKA-002 primary completion](https://sec-api.dev/pdufa/orka-002) | ORKA | Hidradenitis Suppurativa (HS) | scheduled | "NCT07783542 (ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-10 (ESTIMATED); Lead Sponsor Oruka Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07783542)) |
| Oct 2028 to Jan 2029 | [ORKA-002 topline data readout](https://sec-api.dev/pdufa/orka-002) | ORKA | Hidradenitis Suppurativa (HS) | scheduled | "NCT07783542 (ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-10 (ESTIMATED); Lead Sponsor Oruka Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07783542)) |

## Drugs

- [APPROACH (tibulizumab)](https://sec-api.dev/pdufa/tibulizumab) (ZURA)
- [Povofortay (povorcitinib)](https://sec-api.dev/pdufa/povorcitinib) (INCY)
- [SPY072](https://sec-api.dev/pdufa/spy072) (SYRE)
- [SL-325](https://sec-api.dev/pdufa/sl-325) (STTK)
- [ORKA-002](https://sec-api.dev/pdufa/orka-002) (ORKA)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/hidradenitis-suppurativa-hs.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Hidradenitis Suppurativa (HS) FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/hidradenitis-suppurativa-hs

```bibtex
@misc{secapidev_indications_hidradenitis_suppurativa_hs_20261116,
  title        = {Hidradenitis Suppurativa (HS) FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/hidradenitis-suppurativa-hs}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_hidradenitis_suppurativa_hs_20261116","title":"Hidradenitis Suppurativa (HS) FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/hidradenitis-suppurativa-hs","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
